MedBud has been incorporated as a non-profit organisation, with Dr. Tahzid Ahsan (Specialist Psychiatrist) joining as medical director Announcement on X/Twitter

Back to Noidecs or All Bud/Flower

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This product was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Terpene Profile (Strain Estimate)

Alpha-PineneMajorPine/Sharp156℃
MyrceneMajorHerbal/Musk166-168℃
CaryophylleneMajorPepper/Spice119℃

MedBud currently tracks 16 common terpenes, more will be added.

No official terpene profile has been provided for this product, information above is estimated based on public strain information.

Dosing Look-Up Table (Estimated)

0.01/g1/mg THC1/mg CBD
0.05/g5/mg THC5/mg CBD
0.1/g10/mg THC10/mg CBD
0.15/g15/mg THC15/mg CBD
0.2/g20/mg THC20/mg CBD
0.25/g25/mg THC25/mg CBD
0.3/g30/mg THC30/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
United Kingdom Noidecs
Designation
T10:C10
Cultivar/Strain
Critical Mass CBD
Classification
Indica Hybrid
Chemotype
Type II: THC/CBD Mix
Flower Provided
Trimmed Whole Flower
THC Potential Range (±10%)
9-11%
CBD Potential Range (±10%)
10%
Cultivated/Produced by
Israel BOL Pharma
Cultivated or Packaged in
Flag of Israel Israel
Irradiation
Gamma-Irradiated
Imported by
United Kingdom Eaststone
Imported as
Schedule II: Finished Product

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Discontinued

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Dispensing Patient Pharmacies

Project Twenty21

Available on T21, a research project offering participating patients several discounted medications:

Product DescriptionPatient Reviews

About Critical Mass CBD

CMCIndica Hybrid

The crossbreeding of Critical Mass and CBD parents has resulted in a highly medicinal strain that features 80% indica and only 20% sativa genetics.

Spanish Flag Spanish Bred, Dutch Flag Dutch Genetics

CBD Critical Mass is a CBD-rich strain that offers medicinal relief alongside some monstrous yields. The crossbreeding of Critical Mass and CBD parents has resulted in a highly medicinal strain that features 80% indica and only 20% sativa genetics. Plants offer buds that contain around 5-10% CBD alongside 5-10% THC, resulting in a ratio of approximately 1:1. This finely-balanced cannabinoid content provides medical relief and symptom management alongside a minor high.

Description provided by CannaConnection.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

United Kingdom About Lyphe Group Ltd

Noidecs Logo

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)